Анализа упоредбе нивоа ЛДХ, β2-МГ, ИЛ-2Р и ИЛ-10 у серуму код пацијената са лимфомом
Нивои серума ЛДХ, β2-МГ, ИЛ-2Р и ИЛ-10 код пацијената са лимфомом
Sažetak
[Objective] To investigate the variations and clinical relevance of blood levels of β2-microglobulin (β2-MG), interleukin (IL)-2R, IL-10, and lactate dehydrogenase (LDH) in patients with lymphoma who have various circumstances.
[Methods] A total of 200 lymphoma patients diagnosed in this hospital from 2021--2025 were selected as the lymphoma group. Serum samples and data such as age, sex, lymphoma tissue, immunological type, clinical stage, bone marrow infiltration, and Epstein–Barr virus (EBV) infection were collected. During the same period, serum samples and data from 80 healthy individuals who underwent physical examinations (the control group) were collected. The levels of serum LDH, β2-MG, IL-2R and IL-10. Changes in the levels of each index in lymphoma tissue, tissue immunological type, clinical stage, bone marrow infiltration, and Epstein–Barr virus (EBV) infection and after effective treatment were analyzed.
[Results] The lymphoma group had greater levels of serum LDH, β2-MG, IL-2R, and IL-10 than the control group (P<0.05). Serum LDH, β2-MG, and IL-2R levels were higher in EBV+ patients than in EBV-patients (P<0.05). Patients with clinical stage III–IV disease and bone marrow infiltration had higher serum levels of LDH, β2-MG, and IL-2R as the disease progressed compared to those with clinical stage Ⅰ–II disease without bone marrow infiltration (P<0.05). Patients with lymphoma had lower serum levels of β2-MG, IL-2R, IL-10, and LDH after treatment than they had before.
[Conclusion] Monitoring the changes in the serum levels of LDH, β2-MG, IL-2R and IL-10 has important clinical value for the auxiliary diagnosis of lymphoma patients, EBV infection, clinical staging, therapeutic effects and prognostic evaluation.
Reference
1.Jin Z, Miao Y, Zhang J, Zhang J, Wang C, Lu X, Miao Y, Sun M, Zhang Y, Zhuang Y, Ni H, Xu J, Zhuang W, Zhao M, Zhu J, Xu M, Lin G, Hua H, Xie X, Xu M, Jia T, Zhai L, Gu W, Shan Q, Wang Z, Shen Q, Zhang X, Li J, Shi W. The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients. Ann Hematol. 2024 Jul;103(7):2257-2266. doi: 10.1007/s00277-024-05631-0. Epub 2024 Jan 25. PMID: 38270644.
2.Im JH, Park SM, An JH, Kim TH, Chae HK, Oh YI, Seo KW, Youn HY. Evaluation of serum interleukin 2 receptor and beta-2-microglobulin as prognostic factors for canine lymphoma: A pilot study. Vet Comp Oncol. 2023 Jun;21(2):184-190. doi: 10.1111/vco.12873. Epub 2023 Jan 31. PMID: 36635848.
3.Li J, Wu Y, Zhang X, Wang X. Causal relationship between beta-2 microglobulin and B-cell malignancies: genome-wide meta-analysis and a bidirectional two-sample Mendelian randomization study. Front Immunol. 2024 Oct 7;15:1448476. doi: 10.3389/fimmu.2024.1448476. PMID: 39434879; PMCID: PMC11491367.
4.Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Bjørn Poulsen C, Ortved Gang A, Brown P, El-Galaly TC, Larsen TS. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma. Cancer Med. 2024 Jun;13(12):e7239. doi: 10.1002/cam4.7239. PMID: 38888359; PMCID: PMC11184650.
5.Kang S, Cho H, Kim S, Lee K, Kang EH, Park JS, Lee YS, Park CS, Go H, Huh J, Ryu JS, Lee SW, Kim SJ, Kim WS, Yoon SE, Ko YH, Suh C. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK. Cancer Res Treat. 2023 Jan;55(1):314-324. doi: 10.4143/crt.2022.015. Epub 2022 Mar 31. PMID: 35381163; PMCID: PMC9873344.
6.Liu J, Gao F, Zhang T, Wang J, Li Z, Liu L, Zhou H, Zhang X, Sun X, Zhang W, Xu B, Su L, Wen S, Tao R, Bai O, Zou L, Li L, Qiu L, Qian Z, Zhou S, Song Y, Zhang Q, Wang X, Zhang H. Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicenter analysis. Br J Hematol. 2024 Nov;205(5):1815-1824. doi: 10.1111/bjh.19770. Epub 2024 Sep 26. PMID: 39327747.
7.Yang YZ, Xu YR, Zhou M, Xu WY, Zhou LQ, Guo ZX. [Significance of Serum β2-Microglobulin for Survival and Relapse of Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Aug;33(4):1057-1062. Chinese. doi: 10.19746/j.cnki.issn.1009-2137.2025.04.019. PMID: 40936130.
8.Vassilakopoulos TP, Arapaki M, Diamantopoulos PT, Liaskas A, Panitsas F, Siakantaris MP, Dimou M, Kokoris SI, Sachanas S, Belia M, Chatzidimitriou C, Konstantinou EA, Asimakopoulos JV, Petevi K, Boutsikas G, Kanellopoulos A, Piperidou A, Lefaki ME, Georgopoulou A, Kopsaftopoulou A, Zerzi K, Drandakis I, Dimopoulou MN, Kyrtsonis MC, Tsaftaridis P, Plata E, Variamis E, Tsourouflis G, Kontopidou FN, Konstantopoulos K, Pangalis GA, Panayiotidis P, Angelopoulou MK. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients. Cancers (Basel). 2024 Jan 5;16(2):238. doi: 10.3390/cancers16020238. PMID: 38254729; PMCID: PMC10813286.
9.Zduniak A, Lévêque E, Draye-Carbonnier S, Becker S, Tonnelet D, Dubois S, Vera P, Tilly H, Jardin F, Decazes P, Camus V. Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients. Hematol Oncol. 2025 Jan;43(1):e70010. doi: 10.1002/hon.70010. PMID: 39676608; PMCID: PMC11647558.
10.Zhang X, Zhang Y, Zhuang Z, Zhao C, Gao F, Dai RP, Yu WH, Chen YX, Zhang W, Zhang MF. Cerebrospinal Fluid Interleukin-10 Biomarker for Vitreoretinal Lymphoma. Am J Ophthalmol. 2023 Feb;246:242-250. doi: 10.1016/j.ajo.2022.10.009. Epub 2022 Oct 28. PMID: 39110157.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Wu H, Sun HC, Ouyang GF. Effect of T-regulatory cells and interleukin-35, interleukin-10, and transforming growth factor-beta on diffuse large B-cell lymphoma. World J Clin Cases. 2023 Oct 16;11(29):7075-7081. doi: 10.12998/wjcc.v11.i29.7075. PMID: 37946782; PMCID: PMC10631411.
13.Carreras J, Kikuti YY, Miyaoka M, Hiraiwa S, Tomita S, Ikoma H, Kondo Y, Ito A, Nagase S, Miura H, Roncador G, Colomo L, Hamoudi R, Campo E, Nakamura N. Mutational Profile and Pathological Features of a Case of Interleukin-10 and RGS1-Positive Spindle Cell Variant Diffuse Large B-Cell Lymphoma. Hematol Rep. 2023 Mar 12;15(1):188-200. doi: 10.3390/hematolrep15010020. PMID: 36975733; PMCID: PMC10048669.
14.Mishina T, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yamada K, Moritsubo M, Inoue-Mitsuyama K, Shimasaki Y, Imamoto T, Kawamoto K, Furuta T, Kohno K, Kato K, Akashi K, Ohshima K. Coexpression of regulatory B-cell markers, transforming growth factor β and interleukin-10 as a prognostic factor in diffuse large B-cell lymphoma. Pathol Res Pract. 2024 Feb;254:155117. doi: 10.1016/j.prp.2024.155117. Epub 2024 Jan 10. PMID: 38262270.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
16.Metayer C, Kodjikian L, Nguyen AM, Loria O, Chaperon M, Ghesquieres H, Mathis T. INTEREST OF REGULAR ASSAYS OF AQUEOUS HUMOR INTERLEUKIN-10 LEVELS IN MONITORING OF VITREORETINAL LYMPHOMA. Retina. 2024 Oct 1;44(10):1807-1813. doi: 10.1097/IAE.0000000000004165. PMID: 39287544.
17.Wang W, Zou D, Zhuang Z, Zhang X, Zhang L, Yin J, Jia C, Yuan L, Cai H, Zhang Y, Wang X, Zhang M, Zhou D, Zhang W. Cell-Free DNA in Cerebrospinal Fluid Complements the Monitoring Value of Interleukin-10 in Newly Diagnosed Primary Central Nervous System Lymphoma. J Oncol. 2023 Jan 4;2023:5808731. doi: 10.1155/2023/5808731. PMID: 36644235; PMCID: PMC9836788.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19.Villanueva-Castro E, Flores-Vázquez JG, Hernández Reséndiz R, Rodríguez-Hernández LA, Rodríguez-Hernández IA, Villalobos-Díaz R, Moncada-Habib T, Muñuzuri-Camacho MA, Mateo-Nouel EJ, Wong-Achi X, Palacios-Rodríguez RA, Cacho-Díaz B, Gutierrez-Aceves GA, Moreno-Jiménez S, González-Aguilar A. Diagnostic Performance of CSF Interleukin-10 in Primary Central Nervous System Lymphoma: A Retrospective Study. Cureus. 2025 Jul 30;17(7):e89063. doi: 10.7759/cureus.89063. PMID: 40895937; PMCID: PMC12396576.
20.Zhang J, Qin S, Jin Z, Chen Q, Xing L, Qiu T, Xia Y, Liang J, Zhu H, Wang L, Fan L, Xu W, Li J, Miao Y. The Clinical Significance and Prognostic Role of Whole-Blood Epstein‒Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. J Clin Immunol. 2023 Aug;43(6):1302-1310. doi: 10.1007/s10875-023-01493-9. Epub 2023 Apr 24. PMID: 37093406.
21.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
22.Omachi T, Atsumi N, Yamazoe T, Yamanouchi S, Matsuno R, Kitawaki T, Kaneko K. Differential Diagnosis of Histiocytic Necrotizing Lymphadenitis and Malignant Lymphoma with Simple Clinical Findings. Children (Basel). 2022 Feb 20;9(2):290. doi: 10.3390/children9020290. PMID: 35205010; PMCID: PMC8870061.
23.Hill HA, Jain P, Ok CY, Sasaki K, Chen H, Wang ML, Chen K. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Res Commun. 2023 Aug 2;3(8):1435-1446. doi: 10.1158/2767-9764.CRC-23-0083. PMID: 37538987; PMCID: PMC10395375.
24.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
25.Fonghem P, Pisitkun T, Rattanapinyopituk K, Sirivisoot S, Rungsipipat A. Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach. Vet World. 2022 May;15(5):1333-1340. doi: 10.14202/vetworld.2022.1333-1340. Epub 2022 May 26. PMID: 35765478; PMCID: PMC9210836.
26.Kagan KBT, Guz D, Buchrits S, Gurion R, Vaxman I, Priss M, Groshar D, Catalano OA, Sherban A, Raanani P, Gafter-Gvili A, Bernstine H. Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2290-2299. doi: 10.1007/s00259-022-05683-2. Epub 2022 Jan 26. PMID: 35079846.
27.Valente M, Sanches JA, Nukui Y, Cury-Martins J, Souza BC, Pereira J, Miyashiro D. Characterization of adult T-cell leukemia/lymphoma patients with specific skin lesions in a tertiary dermatological service in Brazil. Front Med (Lausanne). 2025 Feb 6;12:1505865. doi: 10.3389/fmed.2025.1505865. PMID: 39991055; PMCID: PMC11842934.
28.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
29.Bohn JP, Stolzlechner V, Göbel G, Pirklbauer M, Wolf D, Steiner N. Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function. Leuk Lymphoma. 2024 Dec;65(14):2108-2115. doi: 10.1080/10428194.2024.2394583. Epub 2024 Aug 21. PMID: 39165182.
30.Wan X, Guo W, Wang X, Li J, Zhao Y, Feng X, Young KH, Bai O. Improving the prognostic ability of PET/CT SUVmax to identify follicular lymphoma with early treatment failure. Am J Cancer Res. 2022 Aug 15;12(8):3857-3869. PMID: 36119824; PMCID: PMC9442020.
31.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
32.Liu Y, Sheng L, Hua H, Zhou J, Zhao Y, Wang B. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231180785. doi: 10.1177/15330338231180785. PMID: 37551117; PMCID: PMC10408319.
33.Tobin JWD, Chikatamarla VA, Matic M, Griffin A, Chowdhury R, Salvaris R, Goh A, Black H, Tong TH, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Steinepreis E, Chen Y, Li L, Broadby G, Gutta N, Morris K, Cochrane T, Trotman J, Talaulikar D, Shortt J, Hodges G, Hawkes EA, Cheah CY, Barraclough A, Manos K, Johnston A, Royle J, Mondello P, Ansell SM, Hapgood G. Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy. Blood Neoplasia. 2024 Oct 8;1(4):100044. doi: 10.1016/j.bneo.2024.100044. PMID: 40552131; PMCID: PMC12182845.
34.Shang J, Zhou X, Liu B, Hu S, Wang X. Novel serous effusion-related risk models and biomarkers for predicting prognosis in T-cell lymphoma patients. Ann Hematol. 2024 Dec;103(12):5557-5572. doi: 10.1007/s00277-024-06109-9. Epub 2024 Nov 28. PMID: 39604596.
35.Chen W, Liu H, Hou SL, Li X, Li L, Lian K, Wu XB, Zhang X. A retrospective study at a single center examining risk factors associated with central nervous system involvement in individuals diagnosed with diffuse large B-cell lymphoma. Clin Neurol Neurosurg. 2024 Sep;244:108454. doi: 10.1016/j.clineuro.2024.108454. Epub 2024 Jul 14. PMID: 39047392.
2.Im JH, Park SM, An JH, Kim TH, Chae HK, Oh YI, Seo KW, Youn HY. Evaluation of serum interleukin 2 receptor and beta-2-microglobulin as prognostic factors for canine lymphoma: A pilot study. Vet Comp Oncol. 2023 Jun;21(2):184-190. doi: 10.1111/vco.12873. Epub 2023 Jan 31. PMID: 36635848.
3.Li J, Wu Y, Zhang X, Wang X. Causal relationship between beta-2 microglobulin and B-cell malignancies: genome-wide meta-analysis and a bidirectional two-sample Mendelian randomization study. Front Immunol. 2024 Oct 7;15:1448476. doi: 10.3389/fimmu.2024.1448476. PMID: 39434879; PMCID: PMC11491367.
4.Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Bjørn Poulsen C, Ortved Gang A, Brown P, El-Galaly TC, Larsen TS. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma. Cancer Med. 2024 Jun;13(12):e7239. doi: 10.1002/cam4.7239. PMID: 38888359; PMCID: PMC11184650.
5.Kang S, Cho H, Kim S, Lee K, Kang EH, Park JS, Lee YS, Park CS, Go H, Huh J, Ryu JS, Lee SW, Kim SJ, Kim WS, Yoon SE, Ko YH, Suh C. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK. Cancer Res Treat. 2023 Jan;55(1):314-324. doi: 10.4143/crt.2022.015. Epub 2022 Mar 31. PMID: 35381163; PMCID: PMC9873344.
6.Liu J, Gao F, Zhang T, Wang J, Li Z, Liu L, Zhou H, Zhang X, Sun X, Zhang W, Xu B, Su L, Wen S, Tao R, Bai O, Zou L, Li L, Qiu L, Qian Z, Zhou S, Song Y, Zhang Q, Wang X, Zhang H. Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicenter analysis. Br J Hematol. 2024 Nov;205(5):1815-1824. doi: 10.1111/bjh.19770. Epub 2024 Sep 26. PMID: 39327747.
7.Yang YZ, Xu YR, Zhou M, Xu WY, Zhou LQ, Guo ZX. [Significance of Serum β2-Microglobulin for Survival and Relapse of Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Aug;33(4):1057-1062. Chinese. doi: 10.19746/j.cnki.issn.1009-2137.2025.04.019. PMID: 40936130.
8.Vassilakopoulos TP, Arapaki M, Diamantopoulos PT, Liaskas A, Panitsas F, Siakantaris MP, Dimou M, Kokoris SI, Sachanas S, Belia M, Chatzidimitriou C, Konstantinou EA, Asimakopoulos JV, Petevi K, Boutsikas G, Kanellopoulos A, Piperidou A, Lefaki ME, Georgopoulou A, Kopsaftopoulou A, Zerzi K, Drandakis I, Dimopoulou MN, Kyrtsonis MC, Tsaftaridis P, Plata E, Variamis E, Tsourouflis G, Kontopidou FN, Konstantopoulos K, Pangalis GA, Panayiotidis P, Angelopoulou MK. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients. Cancers (Basel). 2024 Jan 5;16(2):238. doi: 10.3390/cancers16020238. PMID: 38254729; PMCID: PMC10813286.
9.Zduniak A, Lévêque E, Draye-Carbonnier S, Becker S, Tonnelet D, Dubois S, Vera P, Tilly H, Jardin F, Decazes P, Camus V. Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients. Hematol Oncol. 2025 Jan;43(1):e70010. doi: 10.1002/hon.70010. PMID: 39676608; PMCID: PMC11647558.
10.Zhang X, Zhang Y, Zhuang Z, Zhao C, Gao F, Dai RP, Yu WH, Chen YX, Zhang W, Zhang MF. Cerebrospinal Fluid Interleukin-10 Biomarker for Vitreoretinal Lymphoma. Am J Ophthalmol. 2023 Feb;246:242-250. doi: 10.1016/j.ajo.2022.10.009. Epub 2022 Oct 28. PMID: 39110157.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Wu H, Sun HC, Ouyang GF. Effect of T-regulatory cells and interleukin-35, interleukin-10, and transforming growth factor-beta on diffuse large B-cell lymphoma. World J Clin Cases. 2023 Oct 16;11(29):7075-7081. doi: 10.12998/wjcc.v11.i29.7075. PMID: 37946782; PMCID: PMC10631411.
13.Carreras J, Kikuti YY, Miyaoka M, Hiraiwa S, Tomita S, Ikoma H, Kondo Y, Ito A, Nagase S, Miura H, Roncador G, Colomo L, Hamoudi R, Campo E, Nakamura N. Mutational Profile and Pathological Features of a Case of Interleukin-10 and RGS1-Positive Spindle Cell Variant Diffuse Large B-Cell Lymphoma. Hematol Rep. 2023 Mar 12;15(1):188-200. doi: 10.3390/hematolrep15010020. PMID: 36975733; PMCID: PMC10048669.
14.Mishina T, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yamada K, Moritsubo M, Inoue-Mitsuyama K, Shimasaki Y, Imamoto T, Kawamoto K, Furuta T, Kohno K, Kato K, Akashi K, Ohshima K. Coexpression of regulatory B-cell markers, transforming growth factor β and interleukin-10 as a prognostic factor in diffuse large B-cell lymphoma. Pathol Res Pract. 2024 Feb;254:155117. doi: 10.1016/j.prp.2024.155117. Epub 2024 Jan 10. PMID: 38262270.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
16.Metayer C, Kodjikian L, Nguyen AM, Loria O, Chaperon M, Ghesquieres H, Mathis T. INTEREST OF REGULAR ASSAYS OF AQUEOUS HUMOR INTERLEUKIN-10 LEVELS IN MONITORING OF VITREORETINAL LYMPHOMA. Retina. 2024 Oct 1;44(10):1807-1813. doi: 10.1097/IAE.0000000000004165. PMID: 39287544.
17.Wang W, Zou D, Zhuang Z, Zhang X, Zhang L, Yin J, Jia C, Yuan L, Cai H, Zhang Y, Wang X, Zhang M, Zhou D, Zhang W. Cell-Free DNA in Cerebrospinal Fluid Complements the Monitoring Value of Interleukin-10 in Newly Diagnosed Primary Central Nervous System Lymphoma. J Oncol. 2023 Jan 4;2023:5808731. doi: 10.1155/2023/5808731. PMID: 36644235; PMCID: PMC9836788.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19.Villanueva-Castro E, Flores-Vázquez JG, Hernández Reséndiz R, Rodríguez-Hernández LA, Rodríguez-Hernández IA, Villalobos-Díaz R, Moncada-Habib T, Muñuzuri-Camacho MA, Mateo-Nouel EJ, Wong-Achi X, Palacios-Rodríguez RA, Cacho-Díaz B, Gutierrez-Aceves GA, Moreno-Jiménez S, González-Aguilar A. Diagnostic Performance of CSF Interleukin-10 in Primary Central Nervous System Lymphoma: A Retrospective Study. Cureus. 2025 Jul 30;17(7):e89063. doi: 10.7759/cureus.89063. PMID: 40895937; PMCID: PMC12396576.
20.Zhang J, Qin S, Jin Z, Chen Q, Xing L, Qiu T, Xia Y, Liang J, Zhu H, Wang L, Fan L, Xu W, Li J, Miao Y. The Clinical Significance and Prognostic Role of Whole-Blood Epstein‒Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. J Clin Immunol. 2023 Aug;43(6):1302-1310. doi: 10.1007/s10875-023-01493-9. Epub 2023 Apr 24. PMID: 37093406.
21.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
22.Omachi T, Atsumi N, Yamazoe T, Yamanouchi S, Matsuno R, Kitawaki T, Kaneko K. Differential Diagnosis of Histiocytic Necrotizing Lymphadenitis and Malignant Lymphoma with Simple Clinical Findings. Children (Basel). 2022 Feb 20;9(2):290. doi: 10.3390/children9020290. PMID: 35205010; PMCID: PMC8870061.
23.Hill HA, Jain P, Ok CY, Sasaki K, Chen H, Wang ML, Chen K. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Res Commun. 2023 Aug 2;3(8):1435-1446. doi: 10.1158/2767-9764.CRC-23-0083. PMID: 37538987; PMCID: PMC10395375.
24.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
25.Fonghem P, Pisitkun T, Rattanapinyopituk K, Sirivisoot S, Rungsipipat A. Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach. Vet World. 2022 May;15(5):1333-1340. doi: 10.14202/vetworld.2022.1333-1340. Epub 2022 May 26. PMID: 35765478; PMCID: PMC9210836.
26.Kagan KBT, Guz D, Buchrits S, Gurion R, Vaxman I, Priss M, Groshar D, Catalano OA, Sherban A, Raanani P, Gafter-Gvili A, Bernstine H. Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2290-2299. doi: 10.1007/s00259-022-05683-2. Epub 2022 Jan 26. PMID: 35079846.
27.Valente M, Sanches JA, Nukui Y, Cury-Martins J, Souza BC, Pereira J, Miyashiro D. Characterization of adult T-cell leukemia/lymphoma patients with specific skin lesions in a tertiary dermatological service in Brazil. Front Med (Lausanne). 2025 Feb 6;12:1505865. doi: 10.3389/fmed.2025.1505865. PMID: 39991055; PMCID: PMC11842934.
28.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
29.Bohn JP, Stolzlechner V, Göbel G, Pirklbauer M, Wolf D, Steiner N. Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function. Leuk Lymphoma. 2024 Dec;65(14):2108-2115. doi: 10.1080/10428194.2024.2394583. Epub 2024 Aug 21. PMID: 39165182.
30.Wan X, Guo W, Wang X, Li J, Zhao Y, Feng X, Young KH, Bai O. Improving the prognostic ability of PET/CT SUVmax to identify follicular lymphoma with early treatment failure. Am J Cancer Res. 2022 Aug 15;12(8):3857-3869. PMID: 36119824; PMCID: PMC9442020.
31.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
32.Liu Y, Sheng L, Hua H, Zhou J, Zhao Y, Wang B. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231180785. doi: 10.1177/15330338231180785. PMID: 37551117; PMCID: PMC10408319.
33.Tobin JWD, Chikatamarla VA, Matic M, Griffin A, Chowdhury R, Salvaris R, Goh A, Black H, Tong TH, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Steinepreis E, Chen Y, Li L, Broadby G, Gutta N, Morris K, Cochrane T, Trotman J, Talaulikar D, Shortt J, Hodges G, Hawkes EA, Cheah CY, Barraclough A, Manos K, Johnston A, Royle J, Mondello P, Ansell SM, Hapgood G. Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy. Blood Neoplasia. 2024 Oct 8;1(4):100044. doi: 10.1016/j.bneo.2024.100044. PMID: 40552131; PMCID: PMC12182845.
34.Shang J, Zhou X, Liu B, Hu S, Wang X. Novel serous effusion-related risk models and biomarkers for predicting prognosis in T-cell lymphoma patients. Ann Hematol. 2024 Dec;103(12):5557-5572. doi: 10.1007/s00277-024-06109-9. Epub 2024 Nov 28. PMID: 39604596.
35.Chen W, Liu H, Hou SL, Li X, Li L, Lian K, Wu XB, Zhang X. A retrospective study at a single center examining risk factors associated with central nervous system involvement in individuals diagnosed with diffuse large B-cell lymphoma. Clin Neurol Neurosurg. 2024 Sep;244:108454. doi: 10.1016/j.clineuro.2024.108454. Epub 2024 Jul 14. PMID: 39047392.
Objavljeno
2026/03/05
Broj časopisa
Rubrika
Original paper
Sva prava zadržana (c) 2026 Xifeng Xu, Yilin Wen, Rongquan Yao, Jianping Zhang
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.